SCHEMBL6762218

SCHEMBL6762218

CCOc1cc2c(cc1OCC)[C@]1(CC[C@H](C(=O)OCc3ccccc3)CC1)N(CCN(C)C)CC2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.39
GLA P06280 1/20 0.38
EGFR P00533 2/20 0.38
NPC1 O15118 1/20 0.38
ALDH1A1 P00352 1/20 0.38
RAB9A P51151 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
CCR8 P51685 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
LTA4H P09960 1/20 0.36
TSHR P16473 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
HTR1A P08908 1/20 0.36
CHRM5 P08912 1/20 0.36
ADRA2A P08913 1/20 0.36
ADRA2B P18089 1/20 0.36
DRD1 P21728 1/20 0.36
DRD4 P21917 1/20 0.36
DRD5 P21918 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6762217 1.00 MAPT (0.39) MAPTGLAEGFRNPC1ALDH1A1
SCHEMBL6764328 0.92 EGFR (0.39) MAPTGLAEGFRNPC1ALDH1A1
SCHEMBL6764332 0.92 EGFR (0.39) MAPTGLAEGFRNPC1ALDH1A1
SCHEMBL6761603 0.92 GPR183 (0.42) NPC1RAB9AKMT2AL3MBTL1
SCHEMBL6761601 0.92 GPR183 (0.42) NPC1RAB9AKMT2AL3MBTL1
SCHEMBL6757288 0.91 EGFR (0.39) MAPTGLAEGFRNPC1ALDH1A1
SCHEMBL6757285 0.91 EGFR (0.39) MAPTGLAEGFRNPC1ALDH1A1
SCHEMBL6760417 0.90 EGFR (0.42) MAPTGLAEGFRALDH1A1MEN1
SCHEMBL6760418 0.90 EGFR (0.42) MAPTGLAEGFRALDH1A1MEN1
SCHEMBL6764113 0.87 ALDH1A1 (0.42) MAPTEGFRALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040106635-A1 having small-conductance potassium channel (SK) blocking activity TANABE SEIYAKU CO., LTD. (JP) 2004-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106635-A1 having small-conductance potassium channel (SK) blocking activity KCNN1, KCNN2, KCNN3 MAPT 4457/4885GLA 3255/4885EGFR 4879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.